Historical Valuation
Sunshine Biopharma Inc (SBFM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.13 is considered Undervalued compared with the five-year average of -1.60. The fair price of Sunshine Biopharma Inc (SBFM) is between 9.76 to 10.46 according to relative valuation methord. Compared to the current price of 1.37 USD , Sunshine Biopharma Inc is Undervalued By 85.96%.
Relative Value
Fair Zone
9.76-10.46
Current Price：1.37
85.96%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Sunshine Biopharma Inc (SBFM) has a current Price-to-Book (P/B) ratio of 0.24. Compared to its 3-year average P/B ratio of 0.34 , the current P/B ratio is approximately -28.73% higher. Relative to its 5-year average P/B ratio of 0.20, the current P/B ratio is about 17.65% higher. Sunshine Biopharma Inc (SBFM) has a Forward Free Cash Flow (FCF) yield of approximately -117.92%. Compared to its 3-year average FCF yield of -182.13%, the current FCF yield is approximately -35.25% lower. Relative to its 5-year average FCF yield of -112.29% , the current FCF yield is about 5.01% lower.
P/B
Median3y
0.34
Median5y
0.20
FCF Yield
Median3y
-182.13
Median5y
-112.29
Competitors Valuation Multiple
AI Analysis for SBFM
The average P/S ratio for SBFM competitors is 3.90, providing a benchmark for relative valuation. Sunshine Biopharma Inc Corp (SBFM.O) exhibits a P/S ratio of 0.13, which is -96.57% above the industry average. Given its robust revenue growth of 11.64%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for SBFM
1Y
3Y
5Y
Market capitalization of SBFM increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of SBFM in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is SBFM currently overvalued or undervalued?
Sunshine Biopharma Inc (SBFM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.13 is considered Undervalued compared with the five-year average of -1.60. The fair price of Sunshine Biopharma Inc (SBFM) is between 9.76 to 10.46 according to relative valuation methord. Compared to the current price of 1.37 USD , Sunshine Biopharma Inc is Undervalued By 85.96% .
What is Sunshine Biopharma Inc (SBFM) fair value?
SBFM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Sunshine Biopharma Inc (SBFM) is between 9.76 to 10.46 according to relative valuation methord.
How does SBFM's valuation metrics compare to the industry average?
The average P/S ratio for SBFM's competitors is 3.90, providing a benchmark for relative valuation. Sunshine Biopharma Inc Corp (SBFM) exhibits a P/S ratio of 0.13, which is -96.57% above the industry average. Given its robust revenue growth of 11.64%, this premium appears unsustainable.
What is the current P/B ratio for Sunshine Biopharma Inc (SBFM) as of Jan 09 2026?
As of Jan 09 2026, Sunshine Biopharma Inc (SBFM) has a P/B ratio of 0.24. This indicates that the market values SBFM at 0.24 times its book value.
What is the current FCF Yield for Sunshine Biopharma Inc (SBFM) as of Jan 09 2026?
As of Jan 09 2026, Sunshine Biopharma Inc (SBFM) has a FCF Yield of -117.92%. This means that for every dollar of Sunshine Biopharma Inc’s market capitalization, the company generates -117.92 cents in free cash flow.
What is the current Forward P/E ratio for Sunshine Biopharma Inc (SBFM) as of Jan 09 2026?
As of Jan 09 2026, Sunshine Biopharma Inc (SBFM) has a Forward P/E ratio of -2.60. This means the market is willing to pay $-2.60 for every dollar of Sunshine Biopharma Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Sunshine Biopharma Inc (SBFM) as of Jan 09 2026?
As of Jan 09 2026, Sunshine Biopharma Inc (SBFM) has a Forward P/S ratio of 0.13. This means the market is valuing SBFM at $0.13 for every dollar of expected revenue over the next 12 months.